NRXP Company Profile and Key Details

NRXP has shown weak momentum, losing -1.8% over the past week and -31.45% over the past quarter, though year-to-date performance is down -19.56%. Short-term trend indicators are bullishly aligned (SMA20 2.12%, SMA50 -9.99%, SMA200 -27.72%). The stock’s 14-day RSI is 48.26 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.74% below its high and over 22.15% above its low. Average 10-day trading volume of 1.24 million shares is slightly above the 3-month average of 1.05 million, indicating heightened recent market interest.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) closed at $2.41 USD, gaining $0.28 (13.15%) from the previous close of $2.13. The stock is currently mid-range between its 52-week high and low $1.58 and $3.84. With a market capitalization of about $41.66 million, NRx Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 1.00 million shares, trading with heavier-than-usual volume. Headquartered in Wilmington, DE, NRx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan C. Javitt, the company employs approximately 2 people and listed since December 04, 2017. NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

NRx Pharmaceuticals, Inc. has 23.77 million shares outstanding. The public float is 13.61 million shares, elevated short interest at 3.03% of float. This equals 545.48 thousand shares. The short ratio is 2.06 days. Institutional investors hold 28.8% of the float. Insiders own 11.55%. Javitt Daniel C. holds 9.63 million shares, Hurvitz Chaim has 570.00 thousand shares and Polar Asset Management Partners Inc. has 488.04 thousand shares.

NRx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.60. This means the shares are trading above this model’s fair value.

The latest quarter delivered EPS of -$0.18. The next quarter is forecast at $0.01. Next year's EPS is expected at $49.45. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 33 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $18.00. The high target offers 1891.7% upside. The low target suggests 646.89% downside. The mean target is $33.76. This offers 1300.83% upside. NRx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 63.64%. The prior quarter beat by 13.33%. Over the last six quarters, Apple has recorded several small beats. These include -99.91% in August 12, 2024.

NRx Pharmaceuticals, Inc. trades at a P/E ratio of -2.69, slightly below the S&P 500 average, with a price-to-sales ratio of 34.22 and a price-to-book ratio of -4.83 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.97, also below market averages.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares are down -19.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NRx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -2.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.94, suggesting 1183.82% upside. Our AI forecast model points to short-term weakness (-6.22% over two weeks), a medium-term rise (5.81% over three months), and a longer-term loss (-2.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that NRx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.22%, with price expected at $2.26 by April 08, 2026, within a range of $2.14 to $2.39 3-Month Outlook: Projected rise of 5.81%, reaching $2.55 by June 22, 2026, with a range of $1.95 to $2.75. 1-Year Outlook: Projected loss of -2.9%, with price at $2.34 by March 25, 2027, within a range of $0.00 to $0.65.